Company
Company

Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

Alia Therapeutics

Company Type: Therapeutic development

Main focus: Developing CRISPR-based therapies to treat genetic diseases

Company stage: Pre-clinical

Diseases: Autosomal-dominant retinitis pigmentosa and other genetic diseases.

Genome-editing tool: CRISPR-Cas

Funding stage: Seed

Location: Trento, Trentino-Alto Adige, Italy

Website: www.aliatherapeutics.com/en/home/

Pipeline: www.aliatherapeutics.com/en/technology/

Partners:

Alia Therapeutics is a biotechnology company focused on developing CRISPR-based therapies to treat genetic diseases. Alia's research is centered on optimising gene-editing tools to improve safety, precision, and efficiency in therapeutic applications, with the goal of providing targeted treatments for a range of inherited disorders. The company’s first pipeline programme aims to develop a gene-editing treatment for autosomal-dominant retinitis pigmentosa.

Tags

HashtagAlia Therapeutics

Company: Alia Therapeutics
close
Search CRISPR Medicine